

EDCTP Update | December 2023



Contents

- EDCTP end-of-the-year message
- Global Health EDCTP3 publishes 2024 Work Programme with over €140 million in funding opportunities
- BMJ Global Health publishes abstracts from the Eleventh EDCTP Forum
- EMA adopts positive opinion of arpraziquantel for treatment of schistosomiasis in preschool-aged children
- EMA adopts positive opinion of Fexinidazole Winthrop as first oral treatment of acute form of sleeping sickness (rhodesiense) found in East and Southern Africa
- Benin and Somalia join EDCTP Association
- WHO prequalifies R21/Matrix-M malaria vaccine
- EDCTP receives Science Diplomacy Award at the South African Science Forum 2023
- World AIDS Day 2023: 20 years of supporting innovative approaches to fight HIV/AIDS
- PrEPVacc study reports that experimental HIV vaccine regimens likely to be ineffective in preventing HIV acquisition
- Early data shows that the H56:IC31 candidate vaccine did not provide protection against TB recurrence
- Call for expression of interest for technical consultations as part of the WHO Global Research Agenda Setting for Climate Change and Health
- Recent events
- Project news
- EDCTP Fellows
- Publications
- Resources
- Training and funding opportunities
- Mark your calendar

EDCTP end-of-the-year message


2023 has been a milestone year for EDCTP in that we celebrated our [20th anniversary](#) during the [Eleventh EDCTP Forum](#) held in Paris, France, from 7–10 November 2023. Additionally, we have seen numerous EDCTP-funded studies generating data of critical public health importance.

In his end-of-the-year message, Mr Abdoulie Barry, EDCTP Association Acting Executive Director and Director of Finance and Administration, highlights important milestones and events of the past 12 months.

[Read more »](#)



Global Health EDCTP3 publishes 2024 Work Programme with over €140 million in funding opportunities



The 2024 Work Programme describes the activities of the Global Health EDCTP3 for the year, including the calls for proposals that will be published in 2024:

HORIZON-JU-GH-EDCTP3-2024-01-two-stage covering six topics for Research and Innovation Actions (RIA):

- Developing novel, innovative HIV therapeutics for reducing the disease burden of HIV in sub-Saharan Africa
- Research on existing Malaria vaccines and development of new promising candidates
- Accelerating development and integration of therapeutics against Neglected Tropical Diseases (NTDs) in sub-Saharan Africa
- Tackling Antimicrobial Resistance (AMR) through R&D in novel and existing antimicrobials
- New tools, technologies and approaches for vector control in sub-Saharan Africa

- Innovative digital health solutions for sub-Saharan Africa

HORIZON-JU-GH-EDCTP3-2024-02-two-stage covering one topic for Coordination and Support Actions (CSA):

- Global Health EDCTP3 JU training fellowship with return phase

Both calls will be opening on **18 January 2024**, with a **stage 1 deadline of 4 April 2024**.

Read the [Global Health EDCTP3 2024 Work Programme](#) for more information.

BMJ Global Health publishes abstracts from the Eleventh EDCTP Forum



EDCTP Forum
Partnering for Global Health Research Innovation
and Impact in Africa
7—10 November 2023 | Paris, France
Celebrating EDCTP: two decades and beyond

The abstracts of the presentations from the Eleventh EDCTP Forum have been published in a supplement to the BMJ Global Health. A total of 70 abstracts were selected for oral presentations, and 317 abstracts were selected for onsite and virtual poster presentations.

[Read more »](#)

EMA adopts positive opinion of arpraziquantel for treatment of schistosomiasis in preschool-aged children

New milestone reached for the Pediatric Praziquantel Consortium



The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive scientific opinion for arpraziquantel to treat schistosomiasis in preschool-aged children (3 months to 6 years of age). The positive scientific opinion considered all supporting evidence, including the results of the pivotal phase III trial in Côte d'Ivoire and Kenya – which showed excellent efficacy of arpraziquantel, achieving cure rates of 90% or above, and was safe and well tolerated by young children affected by schistosomiasis. This trial was co-funded by EDCTP and the Global Health Innovative Technology (GHIT) through the [PZQ4PSAC study](#).

[Read more »](#)

EMA adopts positive opinion of Fexinidazole Winthrop as first oral treatment of acute form of sleeping sickness (rhodesiense) found in East and Southern Africa



EMA gives positive opinion to Fexinidazole Winthrop as first oral treatment of acute form of sleeping sickness (rhodesiense) found in East and Southern Africa

Use (CHMP) has adopted a positive scientific opinion for the use of Fexinidazole Winthrop as first oral treatment for *T.b. rhodesiense* sleeping sickness, an acute and lethal form of this parasitic disease found in Eastern and Southern Africa. The trial for treatment of *T.b. rhodesiense* with Fexinidazole Winthrop in Malawi and Uganda was supported by EDCTP through the [HAT-r-ACC consortium](#).

[Read more »](#)

Benin and Somalia join EDCTP Association



EDCTP is pleased to welcome Benin and Somalia on board as the newest member countries of the EDCTP Association, bringing the total number of African countries to 28. The admittance of Somalia was approved on 3 October 2023. The admittance of Benin was approved on 1 December 2023. Additionally, both countries formalised their commitment to the EDCTP Association for participation in the Global Health EDCTP3 Joint Undertaking. Benin will be represented in the EDCTP Association General Assembly by Mr Sètondji Géraud Roméo Padonou and Dr Marius Kèdoté, University of Abomey-Calavi. Somalia will be represented by Dr Abdinasir Yusuf Osman and Mr Abdifatah Dirie Ahmed, National Institute of Health, Ministry of Health.

[Read more »](#)

WHO prequalifies R21/Matrix-M malaria vaccine



WHO prequalifies a second malaria vaccine, a significant milestone in prevention of the disease

WHO has added the R21/Matrix-M malaria vaccine to its [list of prequalified vaccines](#). In October 2023, [WHO recommended its use](#) for the prevention of malaria in children. The prequalification of the R21/Matrix-M vaccine, the world's second malaria vaccine, is poised to expand access to malaria prevention through vaccination. The vaccine was developed by the Jenner Institute at Oxford University and Serum Institute of India with support from EDCTP, the Wellcome Trust, and the European Investment Bank.

[Read more »](#)

EDCTP receives Science Diplomacy Award at the South African Science Forum 2023



EDCTP received the [Science Diplomacy Award 2023](#) under the category Global Science, Technology and Innovation (STI) Partnership Achieving Excellence in Global Science, recognising EDCTP's contributions towards harnessing international collaboration to achieve excellence in global science, specifically concerning the fight against infectious

diseases.

The ceremony took place on 6 December 2023, at the official opening of the South African Science Forum in Pretoria, South Africa. The award was given by Honorable Blade Nzimande, South African Minister of Higher Education, Science and Innovation, and received by Dr Michael Makanga, Executive Director of the Global Health EDCTP3, on behalf of EDCTP. This is the [second time](#) EDCTP has been honoured with this award.

World AIDS Day 2023: 20 years of supporting innovative approaches to fight HIV/AIDS



EDCTP's investments in HIV & HIV-associated infections

€193.46 M
In 129 projects on HIV & HIV-associated infections awarded from 2003-2023.

€171.72 M
to support 47 projects with collaborative clinical trials and clinical studies conducted by European-African consortia.

€6.25 M
to support 7 projects that facilitate the translation of research results of medical interventions into policies and practices for national health programmes.

€15.49 M
to support 75 fellowships that focus on the career development of individual researchers.



Supported by the
European Union



Since its inception in 2003, EDCTP has had a strong focus on one of sub-Saharan Africa's greatest health challenges: HIV/AIDS. On World AIDS Day 2023, EDCTP joined partners around the globe to support communities – especially those living with HIV – to lead the way to ending HIV/AIDS. This is also an opportunity to look back and reflect on the impact of the clinical research on HIV and HIV-associated infections EDCTP has supported over the last 20 years of the programme.

[Read more »](#)

PrEPVacc study reports that experimental HIV vaccine regimens likely to be ineffective in preventing HIV acquisition



The first PrEPVacc volunteer participant receives an injection at the Masaka site of the MRC/UVRI and LSHTM Uganda Research Unit, on Tuesday 15 December 2020. (c) PrEPVacc Investigators

The EDCTP-funded [PrEPVacc HIV prevention study](#) has stopped its experimental vaccine regimens as there is little or no chance of the trial demonstrating vaccine efficacy in preventing HIV acquisition. The study has conducted experimental vaccine regimens and a new form of oral pre-exposure prophylaxis (PrEP) in 1,500 participants from East and Southern Africa. The decision to stop vaccinations immediately was based on the recommendations of its independent data monitoring committee. The committee has recommended that the oral PrEP component of the study continue to completion. EDCTP commends the PrEPVacc consortium for their excellent management of this complex trial. We continue to work with the consortium to support the study in generating and analysing the data for future vaccine development. We thank all the trial participants for their cooperation and support to this study.

Read the [full statement](#) from the PrEPVacc study team.

Early data shows that the H56:IC31 candidate vaccine did not provide protection against TB recurrence



The Statens Serum Institut (SSI) announced that they will stop the development of the H56:IC31 tuberculosis (TB) candidate vaccine. The first analyses of data from the phase 2b vaccine trial, conducted under the EDCTP-funded POR TB study, show that the vaccine was well tolerated and was immunogenic. However, the primary analysis showed it did not provide protection against TB recurrence. Dr Pauline Beattie, EDCTP Operations Manager and Scientific Advisor: *"This was a well-conducted study by a Europe-Africa team of highly experienced researchers. Although the results are disappointing, the data will inform decisions about the development of future TB vaccines and as such valuable lessons can be learned from this trial."*

The research team has informed the study participants and national authorities in Tanzania and South Africa of these results. Detailed clinical and lab analyses are underway to understand the mechanisms leading to TB recurrence. The researchers will share all findings with the scientific community to help advance the field. Developing a safe and effective vaccine against TB remains a global priority. EDCTP encourages all stakeholders to work together in the fight against TB.

Read the [full statement](#) from the POR TB Consortium.

Please visit the [EDCTP website](#) for more information about EDCTP's portfolio of TB vaccine projects.

**Call for expression of
interest for technical
consultations as part of
the WHO Global
Research Agenda Setting
for Climate Change and
Health**



WHO is developing an updated research agenda for climate and health. The Research Agenda for Action on Climate Change and Health, REACH 2035 will define a set of forward-looking research priorities on climate change and health. To inform the development of REACH 2035, WHO will hold a series of virtual technical consultations from January to April 2024 with a broad spectrum of stakeholders. Consultations will be held in each of the six WHO regions and at the global level. This open call for expression of interest invites participants with expertise in climate change and health from academic, civil society, community-based, policy, and research organizations to participate in several up to three-hour online consultations.

[Read more »](#)

Recent events

EDCTP at CPHIA 2023

The yearly [CPHIA](#) (International Conference on Public Health in Africa) offers a distinctive platform led by Africans for leaders throughout the continent to review insights gained in health and science. It serves as an opportunity to converge on a collective path forward to enhance the resilience of health systems.

Dr Thomas Nyirenda, Strategic Partnerships & Capacity Development Manager and Head of Africa Office, and Ms Michelle Nderu, Project Officer, represented EDCTP and spoke at and chaired several sessions at the conference.

A side session organised by the Global Health EDCTP3 'Accelerating research in Africa to tackle infectious diseases' explored ideas on how to enable the acceleration of research and innovation in infectious diseases across sub-Saharan Africa. The session was chaired by Dr Jean Marie Vianney Habarugira, Senior Scientific Officer, Global Health EDCTP3, and Dr Thomas Nyirenda, and featured a panel composed of clinical research experts and health research funders.

Additionally, Ms Uchenne Ebenezar, a [TALENT](#) PhD fellow and a health economist, presented two posters on the impact of COVID-19 on health financing mechanisms and the effect of COVID-19 on social health insurance schemes in resource-limited settings and the implications for future pandemic situations.

EDCTP Financial and Project Management Training workshop in Dakar

The EDCTP Financial and Project Management Training workshop in Dakar, Senegal, from

30 November to 1 December 2023 welcomed 40 participants, mostly from West Africa.

The workshop covered managing projects awarded under EDCTP2 and Global Health EDCTP3 programmes. Financial training included the grant agreement, budgets, eligibility of costs, timesheets, person months, currency calculations, internal controls and independent audits. Technical training covered consortia, the grant agreement and Annex 1, ethical issues, clinical studies and data sharing. Information on reporting requirements, deliverables and milestones, and amendments was also shared.

A session on the transition from EDCTP2 to Global Health EDCTP3 programmes highlighted the key differences for applicants and grantees. Overall, the attendees were satisfied by the training they received, as indicated by the “feedback forms” they filled in at the end of the training. Recommendations on training needs will be taken forward in planning future training.

Inauguration of the first BioNTech Africa manufacturing site

An event on 18 December 2023 marked the inauguration of the first BioNTech Africa manufacturing site in Kigali, Rwanda. The inauguration took place on the occasion of the set-up of the first manufacturing unit called BioNTainer. This effort is one of BioNTech’s multiple initiatives aimed at helping to build a sustainable and resilient African vaccine ecosystem and supporting equitable access to novel medicines globally: these cover research and development, clinical trials, manufacturing and local training of specialized personnel.

The event featured several distinguished speakers, including HE Paul Kagame, President of Rwanda; HE Macky Sall, President of Senegal; HE Nana Akufo-Addo, President of Ghana; HE Mia Amor Mottley, Prime Minister of Barbados; HE Moussa Faki Mahamat, Chairperson of the African Union Commission; HE Ursula von der Leyen President of the European Commission; HE Annalena Baerbock, Germany Federal Minister of Foreign Affairs; Hon Dr Mathume Joseph Phaahla, Minister of Health for South Africa; Dr Akinwumi Adesina, President of the African Development Bank. Dr Thomas Nyirenda, Strategic Partnerships & Capacity Development Manager and Head of Africa Office, represented EDCTP at the launch event.

Ghana FELTP 6th Scientific Conference and Competency Graduation

The Ghana Field Epidemiology and Laboratory Training Program ([GFELTP](#)) held its 6th Scientific Conference and Competency Graduation from 13-14 December 2023 in Accra, Ghana.

The theme for the conference and competency graduation was “Advancing Public Health Practice in a Challenging World”. The conference provided a platform for FELTP residents, graduates and other public health professionals to showcase their work in the area of surveillance, outbreak investigations natural/humanitarian disasters and COVID-19-related events over the past years. During the conference, 22 residents from Cohort XIV and XV graduated and were awarded competency certificates. Of these 22 residents who graduated, 15 residents (from DR Congo, The Gambia, Ghana, Liberia, Sierra Leone and Zambia) were funded by EDCTP/Africa CDC through the Training of Epidemiologists in Disease Outbreak and Epidemic Response ([TEDOER](#)) project. Dr Grace Ocansey, one of the EDCTP Fellows, won the best oral presentation award at the conference.

The conference was attended by key stakeholders from the University of Ghana School of Public Health, Ghana Health Services, Centers for Disease Control and Prevention (CDC), World Health Organization (WHO), West African Health Organization (WAHO), Korea International Cooperation Agency (KOICA), African Field Epidemiology Network (AFENET) and EDCTP. Dr Thomas Nyirenda, EDCTP Strategic Partnerships and Capacity Development Manager and Head of Africa Office, joined virtually and made opening remarks highlighting the important contribution of the Master’s Fellows to the workforce in sub-Saharan Africa.


Dutch PDP Annual Meeting

On 29 November 2023, the Netherlands Enterprise Agency (RVO) organised on behalf of the Dutch Ministry of Foreign Affairs the Product Development Partnerships (PDP) Annual meeting in Leiden, the Netherlands. EDCTP was represented at the event by Ms Lara

Pandya, Senior Strategic Partnerships Officer, Dr Michelle Helinski, Senior Project Officer, and Dr Debora Bade, Project Officer. EDCTP General Assembly deputy representatives for the Netherlands, Dr Sarah Spronk, and Mr Peter Derrek Hof of the Dutch Ministry of Foreign Affairs highlighted the Dutch key policies and [Global Health Strategy 2023-2030](#). Several PDPs presented the work they are conducting through the support of the Netherlands through the Dutch [Product Development Partnerships Funds \(PDP III and PDP IV\)](#) as well as other PDP funders, including the EDCTP. PDP III, PDP IV and their predecessor, PDP II, contribute to innovation in the areas of healthcare products and technologies specifically aimed at diseases and conditions related to poverty and sexual and reproductive health and rights (SRHR). The PDP activities funded through these Dutch programmes are part of the EDCTP2 and Global Health EDCTP3 programmes, supported by the European Union. Watch a short [video blog](#) on the event.

Project news

TRREE: updated and expanded e-learning programme



[TRREE](#) (Training and Resources in Research Ethics Evaluation) high quality, free and open-access training in research ethics and regulation for investigators and research ethics committees' members together with easy and direct access to national laws and regulations in health-related research involving human participants. TRREE has launched a complete revision of the first three training modules (introduction to research ethics, research ethics evaluation, and informed consent). The content has been adapted to the latest developments in research ethics with new examples and new evaluation questions.

[Read more »](#)

AMÉLIORER project: strengthening research ethics and regulatory capacities in Benin



The [AMÉLIORER project](#) was set up in response to the need to strengthen the supervision of research carried out in Benin, by improving the system of ethical evaluation and monitoring, and by setting up an accreditation system for institutional research ethics committees. Completed in July 2023, the project has shared its main results and impact.

[Read more »](#)

TESA III annual meeting in Paris

The members of the EDCTP Regional Network of Excellence [TESA](#) (Trials of



Excellence in Southern Africa) met in Paris, France on 11 November 2023. The main goal of the meeting was to share results and evaluate the progress of projects, as well as highlight issues in implementing some activities in institutions that are part of the network. The members have also received updates from the Scientific Review Committee and other ancillary projects and updates from the [TAGENDI](#) project which aims to address gender and diversity regional gaps in clinical research capacity.

[Read more \(in Portuguese\) »](#)

GIFT project completes enrolment



The GIFT project has completed its first in-field clinical study and enrolled 675 women to participate. The study is taking place in Madagascar, South Africa, and Zimbabwe. The GIFT study is developing a lateral flow test that will be able to detect genital inflammation, a sign of sexually transmitted infection. Visit the [GIFT study website](#) for more information.

PediCAP project participation at the Eleventh EDCTP Forum



The PediCAP project aims to investigate antibiotic therapy for severe and very severe childhood community-acquired pneumonia. The project has made available the three poster presentations and the oral presentation based on the project that were presented at the Eleventh EDCTP Forum.

[Read more »](#)

EDCTP Fellows

Fellow profile: Professor Hamtandi Magloire Natama

Professor Hamtandi Magloire Natama (Burkina Faso) earned a PhD in Biomedical Sciences in 2018 at the University of Antwerp in collaboration with the Institute of Tropical Medicine in Antwerp (Belgium), studying genetic and immunological factors contributing to inter-individual variation in susceptibility to malaria in early childhood. After returning to his home institution, he was promoted as associate

[Read more »](#)



Publications

EDCTP is a member of [Europe PMC](#). This enables EDCTP-funded researchers to share their publications via one central location. Sharing publications by EuropePMC also ensures that they will satisfy the requirements for EDCTP-funded research projects: making publications openly accessible as soon as possible. [Submit your manuscript through Europe PMC Plus](#).

- *SSM. Qualitative Research in Health*: [Pathways to care with HIV-associated cryptococcal meningitis in Botswana and Uganda: Findings from a qualitative methods study](#). Lawrence, D S, *et al.* (1 December 2023)
- *Malaria Journal*: [Health workers' adherence to the malaria test, treat and track strategy during the COVID-19 pandemic in malaria high transmission area in Eastern Uganda](#). Mumali, RK, *et al.* (27 November 2023)
- *Malaria Journal*: [Experiences of healthcare personnel on the efficacy of artemisinin-based combination therapy and malaria diagnosis in hospitals in Uganda](#). Ocan, M, *et al.* (27 November 2023)
- *International Journal of Infectious Diseases*: [Identification of the PfK13 mutations R561H and P441L in Democratic Republic of Congo \(DRC\)](#). Kahunu, M, *et al.* (26 November 2023)
- *International Journal of Environmental Research and Public Health*: [Reducing Barriers to COVID-19 Vaccination Uptake: Community Ideas From Urban And Rural Kenya](#). Al-Aghbari, A A, *et al.* (22 November 2023)
- *Heliyon*: [Bacterial microbiome and host inflammatory gene expression in foreskin tissue](#). Maust, B S, *et al.* (14 November 2023)
- *PLoS Pathogens*: [Homologous Ad26.COVS vaccination results in reduced boosting of humoral responses in hybrid immunity, but elicits antibodies of similar magnitude regardless of prior infection](#). Moyo-Gwete, T, *et al.* (9 November 2023)
- *Journal of the Pediatric Infectious Diseases Society*: [First-Line Antituberculosis Drug Concentrations in Infants With HIV and a History of Recent Admission With Severe Pneumonia](#). Chabala, C, *et al.* (1 November 2023)
- *The Journal of Infectious Diseases*: [Randomized field trial to assess the safety and efficacy of dihydroartemisinin-piperazine for seasonal malaria chemoprevention in school-aged children in Bandiagara, Mali](#). Traore, K, *et al.* (8 October 2023)
- *Vaccine (Science Direct)*: [Mapping the timeliness of routine childhood vaccination in The Gambia: A spatial modelling study](#). Wariri, O, *et al.* (7 September 2023)

Resources



[Collaborative clinical R&D](#)
online



[Clinical research capacity](#)
PDF



[Fellowships](#)
online

- EDCTP | [Knowledge Hub: Tools and guidance for conducting clinical research](#)
- EDCTP | [Alumni Network](#)
- ERUDIT | [Planning for Financial Sustainability manual](#)
- Europe PMC webinar | [Watch the recording](#) and [download the slides](#)
- TRUST project | [Video introducing the Global Code of Conduct](#)
- PACTR | [Open access clinical trial registry](#)
- PAVIA project | [PV strengthening blue-print](#)

Training and funding opportunities

EU Award for Gender Equality Champions | Deadline for application: 25 January 2024

This annual prize, launched in 2022, is the European Commission's initiative to recognise and celebrate the outstanding results achieved by European academic and research organisations through the implementation of Gender Equality Plans. The prize is open to universities, higher education institutions, and other research performing organisations (public or private), established in an EU country or a country associated to Horizon Europe. Deadline for submission for the 2023 edition is 25 January 2024 at 17.00 (CET).

[More information »](#)

Leprosy Research Initiative (LRI) calls for proposals | Deadline for application: 26 January 2024

Leprosy Research Initiative (LRI) has announced two new calls for proposals:

- **RESILIENTD call for proposals** (budget round 2025), in collaboration with Anesvad Foundation, which focuses on addressing the social determinants of health in the context of skin NTDs, including leprosy, with a focus on Sub-Saharan Africa.
- **LRI Regular call for proposals** (budget round 2025), which accepts research proposals with a focus on leprosy – including research applications combining leprosy with other diseases that share cross-cutting issues with leprosy.

Both calls open for applications on 1 December 2023, with a deadline of 26 January 2024.

[More information »](#)

Networks of research excellence in epidemic and pandemic sciences across Africa | Deadline for application: 31 January 2024

The [Science for Africa Foundation](#), in partnership with the [Pandemic Sciences Institute](#) at the University of Oxford and the [Mastercard Foundation](#), is releasing a call to establish networks of research excellence in epidemic and pandemic sciences across Africa. Funds are offered for up to six years for the Epidemic Science Leadership and Innovation Networks (EPSILONs), which aim to nurture and promote world-class epidemic and pandemic sciences research and innovation in Africa. A dedicated webinar for applicants took place on 6 December 2023 and the recording can be accessed [here](#).

[More information »](#)

Accelerating Catalyzing Solutions for Climate Change's Impact on Health, Agriculture, and Gender | Deadline for application: 31 January 2024

This Grand Challenges request for proposals seeks innovative research and pilot/feasibility projects utilising transdisciplinary approaches to better adapt to, mitigate, or reverse the combined, deleterious effects of climate change on health, women's lives, and agriculture in the geographies of interest. These innovations include early warning and disease surveillance systems to respond to climate-event-driven surges in malaria and other vector borne diseases, as well as improved mapping of expanded vector ranges and vector-borne disease transmission. Preference will be given to innovations that are formulated locally or adapted from other contexts.

[More information »](#)

NIHR Global Health Research Short Placement Award for Research Collaboration Round 4 | Deadline for application: 15 February 2024

A global health research placement award to meet the academic training and career development needs of NIHR GHR Academy members. Individuals can apply for up to £10,000 to design and undertake a short bespoke placement to increase their research training experience, increase understanding of what different parts of the NIHR offer and enhance their career development and trajectory.

[More information »](#)

NIHR Global Health Research Cohort Academic Development Award Round 3 | Deadline for application: 15 February 2024

The NIHR Global Health Research Cohort Academic Development Award (GHR CADA) scheme enables NIHR GHR Programme Training Leads/Programme Directors to apply for up to £30,000 to deliver training and career development activities. The scheme aims to help GHR programme cohorts primarily focused in low- and middle-income countries to develop skills needed for a successful academic research career.

[More information »](#)

UK FCDO Call for expressions of interest for Product development research for global health | Deadline for application: 23 February 2024

The UK Foreign Commonwealth and Development Office (FCDO) has launched a call for expression of interest for research funding to develop accessible, affordable health products for use in low- and middle-income countries. Interested organisations should submit an expression of interest by 23 February 2024.

[More information »](#)

GFBR Fellowships | Deadline for application: 29 February 2024

Applications are now open for fellowships relating to the Global Forum on Bioethics in Research (GFBR) 2023 topic 'Ethics of health research priority setting'. The GFBR fellowships provide a unique opportunity for the Forum participants to explore ethical issues that have arisen during the course of a GFBR meeting and to establish new collaborations.

[More information »](#)

Mark your calendar

Antimicrobial Chemotherapy Conference | 6-7 February 2024

The Antimicrobial Chemotherapy Conference (ACC2024) will take place virtually from 6-7 February 2024. The conference is jointly organised by the Global Antibiotic Research & Development Programme (GARDP) and the British Society for Antimicrobial Chemotherapy (BSAC). For ACC2024, the collaborating organisations are the European Clinical Research Alliance on Infectious Diseases (ECRAID) and the Netherlands Antibiotic Development Platform (NADP). Abstract submission for a late-breaker for oral and/or poster presentations closes on 8 January 2024. Participation in the virtual conference is free of charge.

[More information »](#)

International Conference on HIV Treatment, Pathogenesis, and Prevention Research (INTEREST) | 14-17 May 2024

The 18th International Conference on HIV Treatment, Pathogenesis, and Prevention Research (INTEREST) will take place from 14-17 May 2024 in Cotonou, Benin. The annual INTEREST Conference is the premier scientific conference for HIV in Africa and brings together scientists involved in HIV treatment, pathogenesis, and prevention research from around the world. The conference will showcase cutting-edge knowledge in the diagnosis and treatment of HIV and the prevention of the HIV-1 infection. Additionally, it will continue to foster the building of a community of African physicians and scientists to facilitate the implementation of local solutions for the management of patients living with HIV-1 infection and for the prevention of HIV transmission. The deadline for abstract submission is 2 February 2024.

[More information »](#)

World Congress of Epidemiology | 24-27 September 2024

The World Congress of Epidemiology (WCE2024) will take place in Cape Town, South Africa from 24-27 September 2024. The theme of WCE2024 is "Epidemiology and complexity: challenges and responses" which will engage the full depth and breadth of methods and practice in contemporary epidemiology. The meeting will feature invited speakers presenting plenary lectures, workshops and interactive sessions. The conference invites submission of abstracts for oral or poster presentations showcasing novel research in epidemiology and public health (general abstract submission deadline: 16 February 2023).

[More information »](#)

EDCTP Communications thanks everyone who provided information for this Update.



EDCTP | Anna van Saksenlaan 51, Den Haag, 2593 HW Netherlands

[Unsubscribe media@edctp.org](mailto:Unsubscribe_media@edctp.org)

[Update Profile](#) | [Constant Contact Data Notice](#)

Sent by media@edctp.org powered by



Try email marketing for free today!